Poly Medicure Limited — Q1 FY26 earnings call

Call held 25 Sep 2025

Management summary

Poly Medicure is aggressively pivoting towards high-technology medical device adjacencies, specifically orthopedics and cardiology, through the acquisitions of Citieffe and PendraCare. The Citieffe acquisition provides a vertically integrated platform in the $12 billion trauma and extremity market with high gross margins and established direct sales channels in the US and Europe. Management is focused on leveraging their global distribution network and R&D capabilities to drive operating leverage and product expansion.

Highlights

  • Acquisition of Citieffe Group (Italy) finalized with an Enterprise Value of €31 million, valued at approximately 10x 2024 EBITDA.

  • Citieffe reported 2024 revenue of €17.3 million, representing 15% YoY growth, with EBITDA of €3.1 million.

  • Gross margins for the acquired orthopedic business are exceptionally high, exceeding 90%.

  • Management targets doubling the Citieffe business within the next 5 years, implying a 10-12% CAGR.

  • PendraCare acquisition was formally closed on September 23, 2025, marking two major inorganic moves in one month.

  • Citieffe holds a 12% market share in Italy and Mexico, with a growing direct sales presence in the US.

  • Identified a major product synergy by introducing 'plates' to Citieffe’s portfolio, a segment representing 40% of the trauma market currently missing from their offering.

Concerns

  • US Market Competition

Key financials

  1. Citieffe Revenue (2024) 17.3 million euro +15%YoY
  2. Citieffe EBITDA (2024) 3.1 million euro +14%YoY
  3. Citieffe Gross Margin 90%
  4. Citieffe EBITDA Margin 17.9%
  5. Acquisition Enterprise Value 31 million euro

What they filed

Q1 FY27: revenue up 30.3%, net profit down 8.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue420 424 441 403 444 +6%494 +17%535 +21%525 +30%
EBITDA115 114 119 106 115 +0%111 −3%110 −8%125 +18%
Net profit87 85 92 93 92 +6%71 −16%65 −29%85 −9%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Orthopedics (Citieffe)
    12% Market Share (Italy)12% Market Share (Mexico)45 Patents

Guidance & targets

Revenue

  • Citieffe Revenue Growth Revenue · next 5 years · High confidence Double business
    with the help of Polymed and our distribution network, we should be able to double the business in the next 5 years.

    — Rahul Gautam, President, Strategy and Corporate Development

  • Citieffe CAGR Revenue · next 5 years · Medium confidence 10% to 12%
    If you look at slightly longer-term trajectory at 10% to 12% CAGR with the help of Polymed...

    — Rahul Gautam, President, Strategy and Corporate Development

  • PendraCare Growth Revenue · FY26 · Medium confidence high single digit to low double digit
    we had mentioned that the asset could grow in high single digit to low double digit on its own currently.

    — Rahul Gautam, President, Strategy and Corporate Development

Capex

  • Regular Annual Capex (Citieffe) Capex · Annual · High confidence 1.5 million to 2 million
    The regular capex for this company is between 1.5 million to 2 million a year.

    — Rahul Gautam, President, Strategy and Corporate Development

Risks & concerns

  • US Market Competition

    high

    The US orthopedic market is dominated by five major players holding 60% share, making expansion for smaller players challenging.

    Management acknowledged

  • Integration Complexity

    medium

    Managing two significant international acquisitions (PendraCare and Citieffe) simultaneously could strain management bandwidth.

    Analyst acknowledged

  • Inventory and SKU Investment

    medium

    Adding 'plates' to the portfolio requires significant capital for multiple SKUs and inventory building.

    Management acknowledged

Areas of evasion (1)

  • Specific product pricing for Citieffe was refused.

Q&A highlights

3 direct
Margin Expansion Potential Direct
Now for us to expand revenue from current 17 million, 18 million revenue to 25 million to 30 million revenue doesn't require significant increase in fixed costs. So that flow-through of margin from gross margin to EBITDA should be better.

Confirms that the business has significant operating leverage due to high gross margins (>90%) and underutilized capacity.

Asked by Karan Gupta, ACMIIL

US Market Sales Strategy Direct
we don't have contracts on the GPO is there, but our own team or what is called a 1099 agents in the US. Those are the people who are distributing those products to trauma centers and hospitals in the US.

Clarifies that the company bypasses traditional GPOs in the US, using direct reps and independent agents, which typically offers better realizations but requires more intensive sales management.

Asked by Jaiveer Shekhawat, Ambit Capital

Product Portfolio Gaps (Plates) Direct
to add a plates as a product, it's a significant investment. You will have to have multiple SKUs, need to create inventory... I'm assuming that was the primary reason that they decide to not invest in this space.

Explains why the previous PE owners (ARCHIMED) didn't expand the portfolio and highlights the specific investment Poly Medicure must make to capture the remaining 40% of the trauma market.

Asked by Harsh Shah, Marcellus

2 min read 5 chapters

Detailed narrative

Strategic Entry into the $12 Billion Trauma Market

The acquisition of Citieffe Group marks Poly Medicure's entry into the high-growth trauma and extremity segment of orthopedics. This segment is valued at $12 billion globally and is growing at 6-7%, faster than the overall orthopedic market. Citieffe brings a vertically integrated model from R&D to manufacturing in Bologna, Italy, with products already MDR-certified for the European market.

Financial Rationale and Operating Leverage

Poly Medicure paid €31 million (Enterprise Value) for Citieffe, representing a 10x multiple of 2024 EBITDA. The business boasts gross margins exceeding 90%, though EBITDA margins are currently lower at 17-18% due to high sales and marketing costs associated with direct presence. Management expects significant margin expansion as revenue grows from €17 million toward €30 million, utilizing existing 40% spare capacity without major incremental fixed costs.

Synergy through Product Expansion: The 'Plates' Opportunity

A key growth lever identified is the introduction of orthopedic plates, which currently represent 40% of the trauma market but are missing from Citieffe's portfolio. By adding plates, Citieffe will be able to participate in comprehensive public tenders where nails and plates are often bundled. This expansion requires significant SKU and inventory investment but is viewed as 'low-hanging fruit' for revenue growth.

US and Global Market Expansion Strategy

The US market represents 67% of global orthopedic sales and offers significantly higher realizations. Citieffe currently uses a network of direct sales reps and 1099 agents in the US. Poly Medicure plans to expand this sales force to increase hospital coverage. Additionally, they aim to leverage their existing global distribution network to introduce Citieffe products into markets where the company currently has no presence.

Inorganic Strategy and Integration Roadmap

With the closure of both PendraCare (Cardiology) and Citieffe (Orthopedics) in September 2025, management indicated a period of 'pause and absorb' to focus on integration. An executive committee led by MD Himanshu Baid and Rishi Baid will oversee the integration, focusing on driving synergies in sales, manufacturing, and R&D. There are long-term plans to potentially move some manufacturing processes to India to improve cost competitiveness for sensitive markets.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls